Clindamycin (Cleocin, Cleocin-T, Clindacin) — 2026 Medicare Part D coverage
clindamycin — sold as Cleocin, Cleocin-T, Clindacin, Clindesse: 23 forms appear in Medicare Part D formularies for 2026. This page reports what plans filed with CMS; it does not recommend a plan.
Which plans in your county cover clindamycin?
Pick a county to see every Medicare Advantage plan filed there and every stand-alone Part D plan in its region, with this drug's tier, restrictions and tier cost sharing.
How to read drug coverage
Tier is the cost-sharing tier the plan assigned the drug in its CMS formulary filing; lower tiers usually cost less. PA = prior authorization, ST = step therapy (try another drug first), QL = quantity limit. Not on formulary means the plan did not list this exact form; the plan may cover another strength or a formulary exception may be possible. Cost sharing is the plan's initial-coverage amount for the tier as filed with CMS; the deductible, the $2,100 annual out-of-pocket cap, the $35 insulin cap and negotiated prices for selected drugs can change what you actually pay. Formularies change during the year; the plan's formulary document and Medicare.gov govern.
What the star rating under each Medicare Advantage plan means
What the star rating means. CMS rates every Medicare Advantage contract (the "H" number in the plan ID — all plans under it share the rating) on a 1-to-5 scale each October, from about 40 measures of care quality, member experience, complaints and appeals, customer service and, for plans with drug coverage, drug safety and pricing. The 2026 rating is largely based on performance measured in 2024.
5 Excellent4 Above average3 Average2 Below average1 Poor
Not rated means CMS published no overall rating — usually a contract too new to be measured or with too few members ("not enough data"); it is not a low score. A 5-star contract can be joined outside the normal enrollment windows (the 5-star Special Enrollment Period, Dec 8 – Nov 30). Medicare.gov flags contracts rated below 3 stars for three years running as low-performing. Stars describe the contract's past performance as CMS measured it; they are not a recommendation, and they do not tell you whether a plan's network, drugs or costs fit you.
Forms and strengths in 2026 formularies
| Form | Formularies listing it | Most common tier | PA | ST | QL |
|---|---|---|---|---|---|
| clindamycin HCl 150 MG Oral Capsule generic · RxCUI 197518 | 328 (100%) | 2 | 0 | 0 | 0 |
| clindamycin HCl 300 MG Oral Capsule generic · RxCUI 284215 | 328 (100%) | 2 | 0 | 0 | 0 |
| clindamycin phosphate 2 % Vaginal Cream generic · RxCUI 309337 | 328 (100%) | 3 | 0 | 0 | 0 |
| clindamycin phosphate 1 % Topical Solution generic · RxCUI 309333 | 327 (100%) | 2 | 0 | 0 | 250 |
| clindamycin HCl 75 MG Oral Capsule generic · RxCUI 309329 | 326 (99%) | 2 | 0 | 0 | 0 |
| clindamycin 900 MG in 6 ML Injection generic · RxCUI 1737581 | 323 (98%) | 4 | 32 | 0 | 0 |
| clindamycin 300 MG in 2 ML Injection generic · RxCUI 1737244 | 316 (96%) | 4 | 28 | 0 | 0 |
| clindamycin 600 MG in 4 ML Injection generic · RxCUI 1737578 | 305 (93%) | 4 | 28 | 0 | 0 |
| clindamycin phosphate 1 % Twice-Daily Topical Gel generic · RxCUI 2676585 | 246 (75%) | 3 | 0 | 0 | 153 |
| clindamycin 300 MG in 50 ML Injection generic · RxCUI 309339 | 244 (74%) | 4 | 28 | 0 | 0 |
| clindamycin phosphate 1 % Topical Lotion generic · RxCUI 197519 | 242 (74%) | 3 | 0 | 0 | 184 |
| clindamycin palmitate HCl 75 MG in 5 mL Oral Solution generic · RxCUI 562266 | 241 (73%) | 4 | 0 | 0 | 0 |
| clindamycin 900 MG in 50 ML Injection generic · RxCUI 309336 | 240 (73%) | 4 | 28 | 0 | 0 |
| clindamycin 600 MG in 50 ML Injection generic · RxCUI 309335 | 234 (71%) | 4 | 28 | 0 | 0 |
| clindamycin phosphate 1 % Once-Daily Topical Gel generic · RxCUI 309332 | 234 (71%) | 3 | 50 | 0 | 150 |
| clindamycin 1 % Medicated Pad generic · RxCUI 797274 | 212 (65%) | 2 | 0 | 0 | 51 |
| Clindacin Pledget 1 % Medicated Pad brand · RxCUI 1091339 | 68 (21%) | 4 | 0 | 0 | 8 |
| clindamycin phosphate 1 % Topical Foam generic · RxCUI 477451 | 19 (6%) | 4 | 0 | 0 | 12 |
| Cleocin 100 MG Vaginal Insert brand · RxCUI 882533 | 18 (5%) | 4 | 0 | 0 | 0 |
| Clindacin 1 % Topical Foam brand · RxCUI 2621717 | 11 (3%) | 4 | 0 | 0 | 6 |
| Cleocin 2 % Vaginal Cream brand · RxCUI 882536 | 1 (0%) | 1 | 0 | 0 | 0 |
| Cleocin-T 1 % Topical Lotion brand · RxCUI 804973 | 1 (0%) | 1 | 0 | 0 | 0 |
| Clindesse 2 % Vaginal Cream brand · RxCUI 602427 | 1 (0%) | 4 | 0 | 0 | 0 |
Counts are formularies (of 328) in the CMS file that list the form, and how many of those apply prior authorization (PA), step therapy (ST) or a quantity limit (QL). Many plans share one formulary, so plan counts in a county will differ.
How to read drug coverage
Tier is the cost-sharing tier the plan assigned the drug in its CMS formulary filing; lower tiers usually cost less. PA = prior authorization, ST = step therapy (try another drug first), QL = quantity limit. Not on formulary means the plan did not list this exact form; the plan may cover another strength or a formulary exception may be possible. Cost sharing is the plan's initial-coverage amount for the tier as filed with CMS; the deductible, the $2,100 annual out-of-pocket cap, the $35 insulin cap and negotiated prices for selected drugs can change what you actually pay. Formularies change during the year; the plan's formulary document and Medicare.gov govern.
What the star rating under each Medicare Advantage plan means
What the star rating means. CMS rates every Medicare Advantage contract (the "H" number in the plan ID — all plans under it share the rating) on a 1-to-5 scale each October, from about 40 measures of care quality, member experience, complaints and appeals, customer service and, for plans with drug coverage, drug safety and pricing. The 2026 rating is largely based on performance measured in 2024.
5 Excellent4 Above average3 Average2 Below average1 Poor
Not rated means CMS published no overall rating — usually a contract too new to be measured or with too few members ("not enough data"); it is not a low score. A 5-star contract can be joined outside the normal enrollment windows (the 5-star Special Enrollment Period, Dec 8 – Nov 30). Medicare.gov flags contracts rated below 3 stars for three years running as low-performing. Stars describe the contract's past performance as CMS measured it; they are not a recommendation, and they do not tell you whether a plan's network, drugs or costs fit you.